keyword
https://read.qxmd.com/read/38536949/combination-nano-delivery-systems-remodel-the-immunosuppressive-tumor-microenvironment-for-metastatic-triple-negative-breast-cancer-therapy
#1
JOURNAL ARTICLE
Liya Bai, Hui Liu, Ran You, Xiaoyu Jiang, Tao Zhang, Yunan Li, Tianhe Shan, Zhanyin Qian, Yinsong Wang, Yuanyuan Liu, Chunyu Li
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer for which effective therapies are lacking. Targeted remodeling of the immunosuppressive tumor microenvironment (TME) and activation of the body's immune system to fight tumors with well-designed nanoparticles have emerged as pivotal breakthroughs in tumor treatment. To simultaneously remodel the immunosuppressive TME and trigger immune responses, we designed two potential therapeutic nanodelivery systems to inhibit TNBC. First, the bromodomain-containing protein 4 (BRD4) inhibitor JQ1 and the cyclooxygenase-2 (COX-2) inhibitor celecoxib (CXB) were coloaded into chondroitin sulfate (CS) to obtain CS@JQ1/CXB nanoparticles (NPs)...
March 27, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38536511/repeatability-of-18-f-fdg-uptake-in-metastatic-bone-lesions-of-breast-cancer-patients-and-implications-for-accrual-to-clinical-trials
#2
JOURNAL ARTICLE
Mark Muzi, Lanell M Peterson, Jennifer M Specht, Daniel S Hippe, Alena Novakova-Jiresova, Jean H Lee, Brenda F Kurland, David A Mankoff, Nancy Obuchowski, Hannah M Linden, Paul E Kinahan
BACKGROUND: Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (18 F-FDG) in a cohort of breast cancer patients with bone-dominant metastases to determine response criteria. The thresholds for 95% specificity of change versus no-change were then applied to a second cohort of breast cancer patients with bone-dominant metastases...
March 27, 2024: EJNMMI Research
https://read.qxmd.com/read/38535786/bee-venom-composition-and-anticancer-properties
#3
REVIEW
Goran Gajski, Elina Leonova, Nikolajs Sjakste
Among the various natural compounds used in alternative and Oriental medicine, toxins isolated from different organisms have had their application for many years, and Apis mellifera venom has been studied the most extensively. Numerous studies dealing with the positive assets of bee venom (BV) indicated its beneficial properties. The usage of bee products to prevent the occurrence of diseases and for their treatment is often referred to as apitherapy and is based mainly on the experience of the traditional system of medical practice in diverse ethnic communities...
February 29, 2024: Toxins
https://read.qxmd.com/read/38535080/differences-in-histological-subtypes-of-invasive-lobular-breast-carcinoma-according-to-immunohistochemical-molecular-classification
#4
JOURNAL ARTICLE
Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
UNLABELLED: The technical complexity of gene expression profiling in routine practice has necessitated the use of surrogate molecular classification of breast cancer, based on immunohistochemical analyses. BACKGROUND AND OBJECTIVES: The aim of this study was to compare the differences between histological and molecular subtypes of invasive lobular carcinoma (ILC) of the breast, in order to be able to predict the behavior and prognosis of the disease, as well as to effectively determine therapy...
March 21, 2024: Diagnostics
https://read.qxmd.com/read/38534929/does-pre-emptive-availability-of-predict-2-1-results-change-ordering-practices-for-oncotype-dx-a-multi-center-prospective-cohort-study
#5
JOURNAL ARTICLE
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective cohort study, we evaluated whether use of PREDICT 2.1 would impact physician decision making. For the first 6 months of the study, data on physician use of both PREDICT 2...
February 27, 2024: Current Oncology
https://read.qxmd.com/read/38534790/the-role-of-urothelial-cancer-associated-1-in-gynecological-cancers
#6
REVIEW
Eleni Nousiopoulou, Kleio Vrettou, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Panagiotis Tsikouras, Nikolaos Nikolettos, Konstantinos Nikolettos, Iason Psilopatis
Gynecological cancers (GC) represent some of the most frequently diagnosed malignancies in women worldwide. Long-non-coding RNAs (lncRNAs) are regulatory RNAs increasingly being recognized for their role in tumor progression and metastasis in various cancers. Urothelial cancer-associated 1 (UCA1) is a lncRNA, first found deregulated in bladder cancer, and many studies have exposed its oncogenic effects in more tumors since. However, the role of UCA1 in gynecological malignancies is still unclear. This review aims to analyze and define the role of UCA1 in GC, in order to identify its potential use as a diagnostic, prognostic, or therapeutic biomarker of GC...
March 21, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38534787/unveiling-the-molecular-mechanism-of-trastuzumab-resistance-in-skbr3-and-bt474-cell-lines-for-her2-positive-breast-cancer
#7
JOURNAL ARTICLE
Anna Kokot, Sachin Gadakh, Indrajit Saha, Ewa Gajda, Michał Łaźniewski, Somnath Rakshit, Kaustav Sengupta, Ayatullah Faruk Mollah, Michał Denkiewicz, Katarzyna Górczak, Jürgen Claesen, Tomasz Burzykowski, Dariusz Plewczynski
HER2-positive breast cancer is one of the most prevalent forms of cancer among women worldwide. Generally, the molecular characteristics of this breast cancer include activation of human epidermal growth factor receptor-2 (HER2) and hormone receptor activation. HER2-positive is associated with a higher death rate, which led to the development of a monoclonal antibody called trastuzumab, specifically targeting HER2. The success rate of HER2-positive breast cancer treatment has been increased; however, drug resistance remains a challenge...
March 21, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38533507/cellular-interactions-in-tumor-microenvironment-during-breast-cancer-progression-new-frontiers-and-implications-for-novel-therapeutics
#8
REVIEW
Tosin Akinsipe, Rania Mohamedelhassan, Ayuba Akinpelu, Satyanarayana R Pondugula, Panagiotis Mistriotis, L Adriana Avila, Amol Suryawanshi
The breast cancer tumor microenvironment (TME) is dynamic, with various immune and non-immune cells interacting to regulate tumor progression and anti-tumor immunity. It is now evident that the cells within the TME significantly contribute to breast cancer progression and resistance to various conventional and newly developed anti-tumor therapies. Both immune and non-immune cells in the TME play critical roles in tumor onset, uncontrolled proliferation, metastasis, immune evasion, and resistance to anti-tumor therapies...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38533085/membrane-trafficking-alterations-in-breast-cancer-progression
#9
REVIEW
Andreia Ferreira, Pedro Castanheira, Cristina Escrevente, Duarte C Barral, Teresa Barona
Breast cancer (BC) is the most common type of cancer in women, and remains one of the major causes of death in women worldwide. It is now well established that alterations in membrane trafficking are implicated in BC progression. Indeed, membrane trafficking pathways regulate BC cell proliferation, migration, invasion, and metastasis. The 22 members of the ADP-ribosylation factor (ARF) and the >60 members of the rat sarcoma (RAS)-related in brain (RAB) families of small GTP-binding proteins (GTPases), which belong to the RAS superfamily, are master regulators of membrane trafficking pathways...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38532756/metastatic-progression-of-breast-cancer-along-with-decreased-mitochondrial-cell-death-priming-of-breast-cancer-cells-a-case-report
#10
Yeliz Aka, Hulya Ozdemir, Nese Torun, Filiz Aka Bolat, Ozgur Kutuk
Metastatic breast cancer remains to be a major cause of cancer-related deaths in women. Exploring the molecular mechanisms to identify targetable alterations in progressing breast cancer and developing functional tools to predict therapy response in these patients are needed. In this report, we present a case of breast cancer patient who progressed following surgery and adjuvant endocrine therapy. Radiological and pathological analyses revealed metastasis to liver and brain. Paired liquid biopsies demonstrated acquired ERBB2 mutations in addition to TP53 and PIK3CA mutations, which were also present before progression...
March 2024: Oxford Medical Case Reports
https://read.qxmd.com/read/38532439/bispecific-aptamer-decorated-and-light-triggered-nanoparticles-targeting-tumor-and-stromal-cells-in-breast-cancer-derived-organoids-implications-for-precision-phototherapies
#11
JOURNAL ARTICLE
Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi, Laura Cerchia
BACKGROUND: Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual-targeted nanotherapeutics selectively acting on both tumor and stromal cells may overcome the limits of tumor cell-targeting single-ligand nanomedicine due to the complexity of the tumor microenvironment. METHODS: Gold-core/silica-shell nanoparticles embedding a water-soluble iridium(III) complex as photosensitizer and luminescent probe (Iren -AuSiO2 _COOH) were efficiently decorated with amino-terminated EGFR (CL4) and PDGFRβ (Gint4...
March 26, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38531974/exploring-the-potential-of-ziziphus-nummularia-and-luteolin-7-o-glucoside-as-tubulin-inhibitors-in-cancer-therapy-and-survival
#12
JOURNAL ARTICLE
Sahar Saleh Alghamdi, Sara Abdulaziz Alghashem, Rizwan Ali, Arwa Alsubait, Rasha Saad Suliman, Afrah E Mohammed, Zeyad Alehaideb, Raghad Abdullah Alshafi, Allulu Yousef Alturki, Ishrat Rahman
Cancer is responsible for approximately 10 million deaths worldwide, with 70% of the deaths occurring in low- and middle-income countries; as such safer and more effective anti-cancer drugs are required. Therefore, the potential benefits of Ziziphus nummularia and Ziziphus spina-christi as sources of anti-cancer agents were investigated. Z. nummularia and Z. spina-christi extracts were prepared using chloroform, ethanol, ethyl acetate, and water. The extracts' anti-cancer properties were determined using the MTT Cell Viability Assay in four cancer cell lines: breast (KAIMRC2 and MDA-MB-231), colorectal (HCT8), and liver (HepG2)...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38531796/dna-methylation-regulated-hoxc8-s-role-in-her2-positive-breast-cancer-function-and-its-contribution-to-herceptin-resistance
#13
JOURNAL ARTICLE
Xiaofeng Xie, Sijia Tang, Zhengyang Yu
BACKGROUND: The epidermal growth factor receptor 2 ( HER2 ) is overexpressed in 30% of breast cancers, and this overexpression is strongly correlated with a poor prognosis. Herceptin is a common treatment for HER2-positive breast cancer; however, cancer cells tend to adapt gradually to the drug, rendering it ineffective. The study revealed an association between the methylation status of the Homeobox C8 ( HOXC8 ) gene and tumor development. Therefore, it is of paramount importance to delve into the interaction between HOXC8 and HER2-positive breast cancer, along with its molecular mechanisms...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38531793/characterizing-the-efficacy-and-safety-of-chemotherapy-plus-everolimus-in-her2-negative-metastatic-breast-cancer-harboring-altered-pi3k-akt-mtor
#14
JOURNAL ARTICLE
Rong Wang, Qiao-Yan Zhu, Wei-Wu Ye, Yuan Huang, Zhan-Hong Chen, Ya-Bing Zheng, Xiao Zou, Jian Wang, Dan-Lu Jiang, Xiao-Jia Wang, Zheng-Yang Xu, Wen-Ming Cao
BACKGROUND: The clinical outcomes of chemotherapy (CT) for the treatment of metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) have proven to be disappointing. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, a tumor-promoting signaling cascade frequently mutated in breast cancer (BC), has been implicated in chemoresistance...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38531630/ezetimibe-inhibits-the-migration-and-invasion-of-triple-negative-breast-cancer-cells-by-targeting-tgf%C3%AE-2-and%C3%A2-emt
#15
JOURNAL ARTICLE
Lingkai Kong, Qinyu He, Ding Ma, Weiwei Shi, Qilei Xin, Chunping Jiang, Junhua Wu
The important role of cholesterol in tumor metastasis has been widely studied in recent years. Ezetimibe is currently the only selective cholesterol uptake inhibitor on the market. Here, we explored the effect of ezetimibe on breast cancer metastasis by studying its impact on breast cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT). Differential gene expression analysis and validation were also carried out to compare ezetimibe-treated and untreated breast cancer cells. Finally, breast cancer cells overexpressing TGFβ2 were constructed, and the effect of TGFβ2 on the migration and invasion of ezetimibe-treated breast cancer cells was examined...
March 26, 2024: FEBS Open Bio
https://read.qxmd.com/read/38531528/regulatory-and-therapeutic-implications-of-competing-endogenous-rna-network-in-breast-cancer-progression-and-metastasis-a-review
#16
REVIEW
I Saranya, V Sowfika Dharshini, R L Akshaya, P Sakthi Subhashini, N Selvamurugan
Breast cancer (BC) is a global health concern, and development of diagnostic tools and targeted treatments for BC remains challenging. Therapeutic approaches for BC often involve a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and hormone therapy. In recent years, there has been a growing interest in the role of noncoding RNAs (ncRNAs), including long ncRNAs (lncRNAs) and microRNAs (miRNAs), in BC and their therapeutic implications. Various biological processes such as cell proliferation, migration, and apoptosis rely on the activities of these ncRNAs, and their dysregulation has been implicated in BC progression...
March 24, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38531482/dipeptidyl-peptidase-9-regulates-the-dynamics-of-tumorigenesis-and-metastasis-in-breast-cancer
#17
JOURNAL ARTICLE
Lisa Heß, Kazeera Aliar, Barbara T Grünwald, Ricarda Griffin, Alina Lozan, Mariel Knöller, Rama Khokha, Tilman Brummer, Thomas Reinheckel
The cytosolic dipeptidyl-aminopeptidase 9 (DPP9) cleaves protein N-termini post-proline or -alanine. Our analysis of DPP9 mRNA expression from the TCGA 'breast cancer' data set revealed that low/intermediate DPP9 levels are associated with poor overall survival of breast cancer patients. To unravel the impact of DPP9 on breast cancer development and progression, the transgenic MMTV-PyMT mouse model of metastasizing breast cancer was used. In addition, tissue- and time-controlled genetic deletion of DPP9 by the Cre-loxP recombination system was done...
March 24, 2024: Biochimica et Biophysica Acta. Molecular Basis of Disease
https://read.qxmd.com/read/38531198/mammary-tissue-derived-extracellular-matrix-hydrogels-reveal-the-role-of-irradiation-in-driving-a-pro-tumor-and-immunosuppressive-microenvironment
#18
JOURNAL ARTICLE
Tian Zhu, Steven M Alves, Arianna Adamo, Xiaona Wen, Kevin C Corn, Anastasia Shostak, Shereena Johnson, Nicholas D Shaub, Shannon E Martello, Benjamin C Hacker, Antonio D'Amore, Rizia Bardhan, Marjan Rafat
Radiation therapy (RT) is essential for triple negative breast cancer (TNBC) treatment. However, patients with TNBC continue to experience recurrence after RT. The role of the extracellular matrix (ECM) of irradiated breast tissue in tumor recurrence is still unknown. In this study, we evaluated the structure, molecular composition, and mechanical properties of irradiated murine mammary fat pads (MFPs) and developed ECM hydrogels from decellularized tissues (dECM) to assess the effects of RT-induced ECM changes on breast cancer cell behavior...
March 21, 2024: Biomaterials
https://read.qxmd.com/read/38531147/mob-cbam-a-dual-channel-attention-based-deep-learning-generalizable-model-for-breast-cancer-molecular-subtypes-prediction-using-mammograms
#19
JOURNAL ARTICLE
Iqra Nissar, Shahzad Alam, Sarfaraz Masood, Mohammad Kashif
BACKGROUND AND OBJECTIVE: Deep Learning models have emerged as a significant tool in generating efficient solutions for complex problems including cancer detection, as they can analyze large amounts of data with high efficiency and performance. Recent medical studies highlight the significance of molecular subtype detection in breast cancer, aiding the development of personalized treatment plans as different subtypes of cancer respond better to different therapies. METHODS: In this work, we propose a novel lightweight dual-channel attention-based deep learning model MOB-CBAM that utilizes the backbone of MobileNet-V3 architecture with a Convolutional Block Attention Module to make highly accurate and precise predictions about breast cancer...
March 10, 2024: Computer Methods and Programs in Biomedicine
https://read.qxmd.com/read/38529509/overcoming-brain-derived-therapeutic-resistance-in-her2-breast-cancer-brain-metastasis
#20
Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R Del Bigio, Xin Xu, Amy Wang, Raul Calvo, Abhijeet Kapoor, Juan J Marugan, Mark J Henderson, Thomas Klonisch, Sabine Hombach-Klonisch
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastuzumab +/-HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suitable patient-derived in-vivo models for HER2+ BCBM has compromised the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis...
February 22, 2024: bioRxiv
keyword
keyword
105821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.